person · Reporting owner
Maeusli Heinz Christoph
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lantheus Holdings, Inc.LNTH · Entity 690 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lantheus Holdings, Inc.
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,014 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 4,137 · Balance 30,014 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PROGENICS PHARMACEUTICALS INC
Report date June 19, 2020 · Filed June 23, 2020
Section 16 reporting ended · disclosed 2020-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.01 · Expires 2029-12-13 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-19 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. F2: This option was originally scheduled to vest in annual installments over the five-year period beginning December 13, 2019 and became immediately vested upon the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.01 · Expires 2029-12-13 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-19 · Disposition to issuer · Disposed 16,393 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect.
F2: This option was originally scheduled to vest in annual installments over the five-year period beginning December 13, 2019 and became immediately vested upon the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 18, 2026 20:36 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 4,137 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000209 · form4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,014 Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:40 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 4,543 | $0.00 Strike: $78.81 | $0.00 |
DisclosureSEC source: 0001062993-25-009695 · form4.xml · derivative · entry 2 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,543 Underlying: Common Stock · 4,543 shares Expires 2035-05-14 Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:40 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-009695 · form4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,877 Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:34 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionStock Option (right to buy) · Derivative | 17,481 | $0.00 Strike: $16.17 | $0.00 |
DisclosureSEC source: 0000950170-24-066687 · ownership.xml · derivative · entry 6 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,481 shares Expires 2029-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:34 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 100 | $80.29 | $8,029.00 |
DisclosureSEC source: 0000950170-24-066687 · ownership.xml · nonDerivative · entry 5 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,340 Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:34 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 5,959 | $79.67 | $474,753.53 |
DisclosureSEC source: 0000950170-24-066687 · ownership.xml · nonDerivative · entry 4 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,440 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.29 to $80.22, inclusive. The reporting person undertakes to provide to LNTH any security holder of LNTH or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:34 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 12,307 | $78.95 | $971,637.65 |
DisclosureSEC source: 0000950170-24-066687 · ownership.xml · nonDerivative · entry 3 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,399 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.28 to $79.26, inclusive. The reporting person undertakes to provide to LNTH any security holder of LNTH or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:34 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 7.326 | $77.71 | $569.30 |
DisclosureSEC source: 0000950170-24-066687 · ownership.xml · nonDerivative · entry 2 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,706 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.27 to $78.12, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc. ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:34 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionCommon Stock | 17,481 | $16.17 | $282,667.77 |
DisclosureSEC source: 0000950170-24-066687 · ownership.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2024. Read SEC document |
| May 09, 2024 Filed May 13, 2024 21:07 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 4,853 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0000950170-24-058822 · ownership.xml · derivative · entry 2 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,853 Underlying: Common Stock · 4,853 shares Expires 2034-05-09 Read SEC document |
| May 09, 2024 Filed May 13, 2024 21:07 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,635 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-058822 · ownership.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,551 Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:46 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 3,798 | $0.00 Strike: $99.38 | $0.00 |
DisclosureSEC source: 0000899243-23-013005 · doc4.xml · derivative · entry 2 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,798 Underlying: Common Stock · 3,798 shares Expires 2033-05-11 Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:46 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,012 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-013005 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,916 Read SEC document |
| May 06, 2022 Filed May 10, 2022 20:37 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 3,616 | $0.00 Strike: $64.20 | $0.00 |
DisclosureSEC source: 0000899243-22-017444 · doc4.xml · derivative · entry 2 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,616 Underlying: Common Stock · 3,616 shares Expires 2032-05-06 Read SEC document |
| May 06, 2022 Filed May 10, 2022 20:37 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,180 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017444 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,904 F1 · shares: The restricted stock units cliff vest on May 6, 2023. Read SEC document |
| May 06, 2022 Filed May 12, 2022 21:51 UTC Amendment | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 4,068 | $0.00 Strike: $64.20 | $0.00 |
DisclosureSEC source: 0000899243-22-017805 · doc4a.xml · derivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,068 Underlying: Common Stock · 4,068 shares Expires 2032-05-06 F1 · shares: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. F1 · derivative.underlying_shares: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. F1 · balance_after: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 8,513 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019265 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,724 Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 02:07 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | PurchaseCommon Stock | 1,000 | $18.60 | $18,600.00 |
DisclosureSEC source: 0000899243-21-010796 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,211 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | PurchaseCommon Stock | 1,000 | $18.02 | $18,020.00 |
DisclosureSEC source: 0000899243-21-008993 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,211 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | PurchaseCommon Stock | 1,000 | $19.39 | $19,390.00 |
DisclosureSEC source: 0000899243-21-007812 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,211 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | PurchaseCommon Stock | 1,000 | $20.03 | $20,030.00 |
DisclosureSEC source: 0000899243-21-006896 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,211 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | PurchaseCommon Stock | 1,000 | $17.94 | $17,940.00 |
DisclosureSEC source: 0000899243-21-005462 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,211 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | PurchaseCommon Stock | 1,000 | $16.13 | $16,130.00 |
DisclosureSEC source: 0000899243-21-004199 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,211 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | PurchaseCommon Stock | 1,000 | $15.29 | $15,290.00 |
DisclosureSEC source: 0000899243-21-003300 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,211 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | PurchaseCommon Stock | 1,000 | $15.80 | $15,800.00 |
DisclosureSEC source: 0000899243-21-002499 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,211 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:55 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 1,308 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027286 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,211 F1 · kind: As previously disclosed, the Board of Directors of the Company elected to receive all remaining compensation payable in 2020 in the form of time-based restricted stock units, rather than in cash. The transaction reported in this Form 4 reports the additional restricted stock units earned by the reporting person for the compensation payable in the fourth quarter of 2020, as calculated by the Company on October 1, 2020. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 21:39 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 922 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022156 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,903 F1 · kind: As previously disclosed, including most recently in our Form 10-Q for the fiscal period ended June 30, 2020, the Board of Directors of the Company elected to receive all remaining compensation payable in 2020 in the form of time-based restricted stock units, rather than in cash. The transaction reported in this Form 4 reports the additional restricted stock units earned by the reporting person for the compensation payable through the third quarter of 2020, as finally calculated by the Company on August 10, 2020. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:46 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,393 | Not disclosed Strike: $5.01 | Not disclosed |
DisclosureSEC source: 0001437749-20-013671 · rdgdoc.xml · derivative · entry 2 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,393 shares Expires 2029-12-13 F1 · price: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. F1 · derivative.exercise_date: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:46 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $5.01 | Not disclosed |
DisclosureSEC source: 0001437749-20-013671 · rdgdoc.xml · derivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2029-12-13 F1 · price: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. F2 · price: This option was originally scheduled to vest in annual installments over the five-year period beginning December 13, 2019 and became immediately vested upon the Merger. F1 · derivative.exercise_date: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. F2 · derivative.exercise_date: This option was originally scheduled to vest in annual installments over the five-year period beginning December 13, 2019 and became immediately vested upon the Merger. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:19 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 17,481 | Not disclosed Strike: $16.17 | Not disclosed |
DisclosureSEC source: 0000899243-20-017492 · doc4.xml · derivative · entry 2 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,481 Underlying: Common stock · 17,481 shares Expires 2029-12-13 F1 · price: Received in exchange for a non-qualified stock option to acquire 56,393 shares of Progenics Pharmaceuticals, Inc. ("Progenics") for $5.01 per share, in connection with the merger of Progenics pursuant to the Amended and Restated Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 20, 2020, by and among Lantheus Holdings, Inc. (the "Company"), Plato Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub"), and Progenics, pursuant to which Merger Sub merged with and into Progenics, with Progenics surviving as a wholly owned subsidiary of the Company (the "Merger"). Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:19 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon stock | 5,981 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017492 · doc4.xml · nonDerivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,981 Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 15:16 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 16,393 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001562180-19-006152 · primarydocument.xml · derivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,393 Underlying: Common Stock · 16,393 shares Expires 2029-12-13 F1 · derivative.exercise_date: This stock option becomes exercisable immediately on the date of grant. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 15:16 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001562180-19-006151 · primarydocument.xml · derivative · entry 1 Maeusli Heinz Christoph · CIK 0001788919 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-12-13 F1 · derivative.exercise_date: 5yr 20% On Vest beginning on 13-Dec-2019 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.